
Releases
Jazz Pharmaceuticals Phase 3 LAGOON Trial Fails Primary Endpoint
Jazz Pharmaceuticals announced that its Phase 3 LAGOON trial failed to meet its primary endpoint of overall survival for Zepzelca in patients with relapsed metastatic small cell lung cancer. The study evaluated the drug as both a monotherapy and in combination with irinotecan against standard investigator-selected treatments.

























